



**NATIONAL CANCER INSTITUTE**

**Grant Number:** 1R37CA229810-01A1  
**FAIN:** R37CA229810

**Principal Investigator(s):**

Daniel Jeong  
Jennifer B Permuth (contact), PHD

**Project Title:** Using Radiogenomics to Noninvasively Predict the Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas and Uncover Hidden Biology

Fonner, Margaret  
Director, Office of Sponsored Research  
12902 Magnolia Drive  
MBC-OSR  
Tampa, FL 336129497

**Award e-mailed to:** Awards@moffitt.org

**Period Of Performance:**

**Budget Period:** 07/01/2019 – 06/30/2020

**Project Period:** 07/01/2019 – 06/30/2024

Dear Business Official:

The National Institutes of Health hereby awards a grant in the amount of \$704,393 (see "Award Calculation" in Section I and "Terms and Conditions" in Section III) to H. LEE MOFFITT CANCER CTR & RES INST in support of the above referenced project. This award is pursuant to the authority of 42 USC 241 42 CFR 52 and is subject to the requirements of this statute and regulation and of other referenced, incorporated or attached terms and conditions.

Acceptance of this award including the "Terms and Conditions" is acknowledged by the grantee when funds are drawn down or otherwise obtained from the grant payment system.

Each publication, press release, or other document about research supported by an NIH award must include an acknowledgment of NIH award support and a disclaimer such as "Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under Award Number R37CA229810. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health." Prior to issuing a press release concerning the outcome of this research, please notify the NIH awarding IC in advance to allow for coordination.

Award recipients must promote objectivity in research by establishing standards that provide a reasonable expectation that the design, conduct and reporting of research funded under NIH awards will be free from bias resulting from an Investigator's Financial Conflict of Interest (FCOI), in accordance with the 2011 revised regulation at 42 CFR Part 50 Subpart F. The Institution shall submit all FCOI reports to the NIH through the eRA Commons FCOI Module. The regulation does not apply to Phase I Small Business Innovative Research (SBIR) and Small Business Technology Transfer (STTR) awards. Consult the NIH website <http://grants.nih.gov/grants/policy/coi/> for a link to the regulation and additional important information.

If you have any questions about this award, please contact the individual(s) referenced in Section IV.

Sincerely yours,

Joy Kears  
Grants Management Officer  
NATIONAL CANCER INSTITUTE

Additional information follows

---

**SECTION I – AWARD DATA – 1R37CA229810-01A1****Award Calculation (U.S. Dollars)**

Salaries and Wages	\$164,692
Fringe Benefits	\$35,357
Personnel Costs (Subtotal)	\$200,049
Travel	\$2,430
Other	\$52,834
Subawards/Consortium/Contractual Costs	\$227,165
Publication Costs	\$1,215

Federal Direct Costs	\$483,693
Federal F&A Costs	\$220,700
Approved Budget	\$704,393
Total Amount of Federal Funds Obligated (Federal Share)	\$704,393
<b>TOTAL FEDERAL AWARD AMOUNT</b>	<b>\$704,393</b>

<b>AMOUNT OF THIS ACTION (FEDERAL SHARE)</b>	<b>\$704,393</b>
--	------------------

SUMMARY TOTALS FOR ALL YEARS		
YR	THIS AWARD	CUMULATIVE TOTALS
1	\$704,393	\$704,393
2	\$668,096	\$668,096
3	\$667,793	\$667,793
4	\$667,478	\$667,478
5	\$667,154	\$667,154

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**Fiscal Information:**

<b>CFDA Name:</b>	Cancer Detection and Diagnosis Research
<b>CFDA Number:</b>	93.394
<b>EIN:</b>	1592451713A1
<b>Document Number:</b>	RCA229810A
<b>PMS Account Type:</b>	P (Subaccount)
<b>Fiscal Year:</b>	2019

IC	CAN	2019	2020	2021	2022	2023
CA	8479566	\$704,393	\$668,096	\$667,793	\$667,478	\$667,154

Recommended future year total cost support, subject to the availability of funds and satisfactory progress of the project

**NIH Administrative Data:**

**PCC:** J1ED / **OC:** 414A / **Released:** KEARSEJ 04/04/2019  
**Award Processed:** 04/10/2019 12:06:44 AM

---

**SECTION II – PAYMENT/HOTLINE INFORMATION – 1R37CA229810-01A1**

For payment and HHS Office of Inspector General Hotline information, see the NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm>

---

**SECTION III – TERMS AND CONDITIONS – 1R37CA229810-01A1**

This award is based on the application submitted to, and as approved by, NIH on the above-titled project and is subject to the terms and conditions incorporated either directly or by reference in the following:

- The grant program legislation and program regulation cited in this Notice of Award.
- Conditions on activities and expenditure of funds in other statutory requirements, such as those included in appropriations acts.

- c. 45 CFR Part 75.
- d. National Policy Requirements and all other requirements described in the NIH Grants Policy Statement, including addenda in effect as of the beginning date of the budget period.
- e. Federal Award Performance Goals: As required by the periodic report in the RPPR or in the final progress report when applicable.
- f. This award notice, INCLUDING THE TERMS AND CONDITIONS CITED BELOW.

(See NIH Home Page at <http://grants.nih.gov/grants/policy/awardconditions.htm> for certain references cited above.)

**Research and Development (R&D):** All awards issued by the National Institutes of Health (NIH) meet the definition of “Research and Development” at 45 CFR Part§ 75.2. As such, auditees should identify NIH awards as part of the R&D cluster on the Schedule of Expenditures of Federal Awards (SEFA). The auditor should test NIH awards for compliance as instructed in Part V, Clusters of Programs. NIH recognizes that some awards may have another classification for purposes of indirect costs. The auditor is not required to report the disconnect (i.e., the award is classified as R&D for Federal Audit Requirement purposes but non-research for indirect cost rate purposes), unless the auditee is charging indirect costs at a rate other than the rate(s) specified in the award document(s).

An unobligated balance may be carried over into the next budget period without Grants Management Officer prior approval.

This grant is subject to Streamlined Noncompeting Award Procedures (SNAP).

This award is subject to the requirements of 2 CFR Part 25 for institutions to receive a Dun & Bradstreet Universal Numbering System (DUNS) number and maintain an active registration in the System for Award Management (SAM). Should a consortium/subaward be issued under this award, a DUNS requirement must be included. See <http://grants.nih.gov/grants/policy/awardconditions.htm> for the full NIH award term implementing this requirement and other additional information.

This award has been assigned the Federal Award Identification Number (FAIN) R37CA229810. Recipients must document the assigned FAIN on each consortium/subaward issued under this award.

Based on the project period start date of this project, this award is likely subject to the Transparency Act subaward and executive compensation reporting requirement of 2 CFR Part 170. There are conditions that may exclude this award; see <http://grants.nih.gov/grants/policy/awardconditions.htm> for additional award applicability information.

In accordance with P.L. 110-161, compliance with the NIH Public Access Policy is now mandatory. For more information, see NOT-OD-08-033 and the Public Access website: <http://publicaccess.nih.gov/>.

In accordance with the regulatory requirements provided at 45 CFR 75.113 and Appendix XII to 45 CFR Part 75, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts with cumulative total value greater than \$10,000,000 must report and maintain information in the System for Award Management (SAM) about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently the Federal Awardee Performance and Integrity Information System (FAPIIS)). Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75. This term does not apply to NIH fellowships.

---

## **SECTION IV – CA Special Terms and Conditions – 1R37CA229810-01A1**

Clinical Trial Indicator: No

This award does not support any NIH-defined Clinical Trials. See the NIH Grants Policy Statement Section 1.2 for NIH definition of Clinical Trial.

**INFORMATION:** In accordance with NCI notice ( [NOT-CA-18-037](#)) published in the NIH Guide for Grants and Contracts, and the negotiations between Joy Kearse and Margaret Fonner, this award has been issued as an R37 MERIT Award. The NCI MERIT award provides an opportunity for the grant recipient to request an extension of up to 2 additional years, based on an expedited NCI review of the accomplishments during the initial funding segment. The extension application for this project will be due on March 1, 2023.

**INFORMATION:** In accordance with the National Cancer Institute's (NCI's) Fiscal Year (FY) 2019 funding policies, this award has been issued at 81% of the adjusted requested level\*. Support recommended for future years has been adjusted accordingly.

\*adjusted requested level: The requested level of support with adjustments made in accordance with the budget narrative in the summary statement and applicable grant policies.

**INFORMATION:** This award involves Human Subjects Research. See "Assurance Requirements and Institutional Review Boards" under Part II, Subpart A, Human Subjects, in the [NIH Grants Policy Statement](#), for specific requirements and grantee responsibilities related to the protection of human subjects, which are applicable to and are a term and condition of this award.

This award reflects the National Cancer Institute's acceptance of the certification that all key personnel have completed education on the protection of human subjects, in accordance the [NIH Grants Policy Statement](#), "Education in the Protection of Human Research Subjects."

Any individual involved in the design and conduct of the study that is not included in the certification must satisfy this requirement prior to participating in the project. Failure to comply can result in the suspension and/or termination of this award, withholding of support of the continuation award, audit disallowances, and/or other appropriate action.

**INFORMATION:** This award includes funds awarded for consortium activity. Consortia are to be established and administered as described in the [NIH Grants Policy Statement \(NIH GPS\)](#).

**INFORMATION:** This award, including the budget and the budget period, has been discussed between Joy Kearse of the National Cancer Institute and Margaret Fonner on 2/25/19.

### **STAFF CONTACTS**

The Grants Management Specialist is responsible for the negotiation, award and administration of this project and for interpretation of Grants Administration policies and provisions. The Program Official is responsible for the scientific, programmatic and technical aspects of this project. These individuals work together in overall project administration. Prior approval requests (signed by an Authorized Organizational Representative) should be submitted in writing to the Grants Management Specialist. Requests may be made via e-mail.

**Grants Management Specialist:** Joy Kearse  
**Email:** kearsej@mail.nih.gov **Phone:** 301-631-3002 **Fax:** 301-451-5391

**SPREADSHEET SUMMARY**

**GRANT NUMBER:** 1R37CA229810-01A1

**INSTITUTION:** H. LEE MOFFITT CANCER CTR & RES INST

Budget	Year 1	Year 2	Year 3	Year 4	Year 5
Salaries and Wages	\$164,692	\$168,798	\$158,945	\$146,466	\$147,895
Fringe Benefits	\$35,357	\$36,280	\$34,285	\$31,812	\$32,165
Personnel Costs (Subtotal)	\$200,049	\$205,078	\$193,230	\$178,278	\$180,060
Travel	\$2,430	\$2,430	\$2,430	\$2,430	\$2,430
Other	\$52,834	\$46,285	\$56,571	\$69,911	\$66,471
Subawards/Consortium/Contractual Costs	\$227,165	\$229,482	\$231,866	\$234,324	\$236,851
Publication Costs	\$1,215	\$1,215	\$1,215	\$1,215	\$1,215
TOTAL FEDERAL DC	\$483,693	\$484,490	\$485,312	\$486,158	\$487,027
TOTAL FEDERAL F&A	\$220,700	\$183,606	\$182,481	\$181,320	\$180,127
TOTAL COST	\$704,393	\$668,096	\$667,793	\$667,478	\$667,154

Facilities and Administrative Costs	Year 1	Year 2	Year 3	Year 4	Year 5
F&A Cost Rate 1	72%	72%	72%	72%	72%
F&A Cost Base 1	\$306,528	\$255,008	\$253,446	\$251,834	\$250,176
F&A Costs 1	\$220,700	\$183,606	\$182,481	\$181,320	\$180,127